Jeffrey Turner

Associate Professor of Medicine @yalemed @yalenephrology

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from CV causes (vs. placebo) ca. 2022 from @NEJM #KidneyWk #Nephpearls

👉🏼 https://t.co/PeYaKt4R9m

[Jeffrey Turner @JeffNeph]

@jmdnephdoc doing what he does best at #KidneyWk. Great talk on Hepatorenal Syndrome and kidney injury markers. It’s good to know there is still some value in calculating FeNa. @YaleNephrology @brewster_ursula @virmani_sar

[Jeffrey Turner @JeffNeph]

Watch out world, @YaleNephrology is taking on POCUS!!! Hands on faculty training session with @Yale_EUS and @cmoore433 today in the Yale Sim Lab!!! @Nephronette was inspiring all of us with her skills.